ESMO 2023: Immunotherapy Advancements in Bladder Cancer

Following ESMO 2023, a panel of experts on bladder cancer review recent updates and discuss the evolving treatment landscape, with a focus on non–muscle invasive bladder cancer.

EP. 1: Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

November 30th 2023

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

EP. 2: Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

November 30th 2023

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

EP. 3: Monitoring Patients With NMIBC

December 7th 2023

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

EP. 4: Bladder Cancer: Treatment Options and Managing Adverse Effects

December 7th 2023

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

EP. 5: Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

December 15th 2023

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

EP. 6: Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

December 15th 2023

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

EP. 7: Approach to Collaborative Care in Bladder Cancer

December 21st 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

EP. 8: Key Takeaways on Evolving Bladder Cancer Treatment Landscape

December 21st 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.